The study's conclusion said treatment with narsoplimab was safe and "resulted in clinical response and favorable overall survival."
Omeros shares were down 7% on Wednesday morning.
Price: 4.41, Change: -0.29, Percent Change: -6.17
|PureCycle Technologies Reports Total Liquidity of $5...|
|--SVB Securities Adjusts Price Target on Abeona Ther...|
|--Cantor Fitzgerald Adjusts Price Target on Abeona T...|
|--Citigroup Reinstates International Flavors & Fragr...|
|--Cantor Fitzgerald Adjusts Veru's Price Target to $...|